ArticleJournal of clinical medicine2020
Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Non-steroidal anti-inflammatory agents for treating cystoid macular edema following cataract surgery.The Cochrane database of systematic reviews · 2022Pooled it
- Irvine-Gass Syndrome Personalized Treatment Outcomes: A Retrospective Single-Center Cohort Study.Journal of personalized medicine · 2025Article
- Should Multifocal Intraocular Lenses Become a Standard in Phacoemulsification Cataract Surgery?Journal of clinical medicine · 2023Article
- Complications of pupil expansion devices: a large real-world study.Frontiers in ophthalmology · 2023Article
- Advancements in Postoperative Care after Cataract Surgery.Journal of clinical medicine · 2022Article
- Postoperative complications of combined phacoemulsification and pars plana vitrectomy in diabetic retinopathy patients.Frontiers in medicine · 2022Article
- Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update.Journal of clinical medicine · 2021Review
- Relationship Between Prolonged Intraocular Inflammation and Macular Edema After Cataract Surgery.Translational vision science & technology · 2021Article
- Role of Cold Balanced Salt Solution (BSS) in the Prophylaxis of Cystoid Macular Edema After Cataract Surgery: A Prospective Randomized Study.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the clinical course of pseudophakic cystoid macular edema (PCME) treated with topical non-steroidal anti-inflammatory drugs (NSAIDs).
methodsAn analysis of the clinical course of PCME consisting of 536 eyes of 536 patients from five consecutive randomized clinical trials aimed at the optimization of anti-inflammatory medication in patients undergoing routine cataract surgery. PCME was classified as (i) grade 0a; no macular thickening, (ii) grade 0b; macular thickening (central subfield macular thickness (CSMT) increase of at least 10%) without signs of macular edema, (iii) grade I; subclinical PCME, (iv) grade II; acute PCME, (v) grade III; long-standing PCME. Eyes with PCME classification from grade I onwards were treated with nepafenac 1 mg/mL t.i.d. for two months.
resultsCSMT increase of at least 10% at any postoperative timepoint with cystoid changes-a criterion for PCME-was found in 19 of 536 eyes (total incidence 3.5%). Of these 19 eyes, 13 eyes (total incidence 2.4%) had clinically significant PCME. PCME was considered clinically significant when both of the following visual acuity criteria were fulfilled. At any timepoint after the cataract surgery both the corrected distance visual acuity (CDVA) gain was less than 0.4 decimals from that of preoperative CDVA, and the absolute CDVA level remained below 0.8 decimals. Only one of the 19 eyes with criteria for PCME (total incidence 0.2%, incidence of PCME eyes 5.3%) showed no macular edema resolution within 2 months after topical nepafenac administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.